INTRODUCTION AND OBJECTIVES: The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is to evaluate metabolic syndrome in men with PCa undergoing intermittent ADT.
INTRODUCTION AND OBJECTIVES: The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is to evaluate metabolic syndrome in men with PCa undergoing intermittent ADT.
METHODS: In this longitudinal study, we studied the prevalence of metabolic syndrome and its components in 190 patients who were undergoing intermittent ADT. The metabolic syndrome was defined according to the Adult Treatment Panel III criteria. All metabolic parameters, including lipid profile, blood glucose, blood pressures, and waist circumferences of the patients were measured six and 12 months after treatment.
RESULTS: Mean age of the patients was 67.5 AE 6.74 years. The incidence of metabolic syndrome after six and 12 months was 6.8% and 14.7%, respectively. Analysis of various components of the metabolic syndrome revealed that patients had significantly higher overall prevalence of hyperglycemia, abdominal obesity, and hypertriglyceridemia in their six-and 12-month follow ups, but blood pressure has not been changed in the same period except for diastolic blood pressure after six months.
CONCLUSIONS: Although there was an increased risk of metabolic syndrome in patients receiving intermittent ADT, it was lower than other studies that treated the same patients with continuous ADT. Also it seems that intermittent ADT has less metabolic complications than continuous ADT and could be used as a safe alternative in patients with advanced and metastatic PCa.
Source of Funding: None

MP57-17 POLYMER DELIVERED, SUBCUTANEOUSLY ADMINISTERED LEUPROLIDE ACETATE PROVIDES STABLE AND LONG-TERM DRUG DELIVERY AND TESTOSTERONE SUPPRESSION ACROSS 4 PIVOTAL TRIALS
Franklin Chu*, San Bernardino, CA; John McLane, Fort Collins, CO; Stuart Atkinson, Debbie Boldt-Houle, Lincolnshire, IL; Christopher Pieczonka, Syracuse, NY INTRODUCTION AND OBJECTIVES: Prostate cancer patients receive androgen deprivation therapy (ADT) to suppress testosterone (T) to prevent proliferation of cancer cells. T suppression levels achieved by bilateral orchiectomy remain the gold standard for the target of suppression by ADT. Although the historical threshold definition of castration is T 50 ng/dL, increasing evidence suggests a T lower than 20 ng/dL may improve clinical outcomes, e.g., increased cancer specific survival and delayed disease progression. However, it has not been established what level of serum LA is required to achieve T suppression below this more rigorous threshold. To determine the level of serum leuprolide required to maintain level T suppression 20 ng/dL in prostate cancer patients, data from 4 pivotal trials evaluating long-acting, subcutaneously (SC) administered leuprolide acetate (LA) formulated with a biodegradable polymer were pooled. METHODS: 438 eugonadal prostate cancer patients (age 40-86) were treated with SC-LA 7.5, 22.5, 30, or 45mg delivered with a single dose lasting over 1, 3, 4, or 6 months (n¼120, 117, 90, 111) , respectively in 4 open-label, fixed-dose, pivotal trials. Descriptive statistics were used to summarize the median concentration of leuprolide acetate at each time point as well as to determine level of T suppression.
RESULTS: Over the dosing intervals of the 1, 3, 4 and 6-month SC-LA formulations, median serum leuprolide levels were consistent. In the pooled analysis (n¼66 with PK assessments), 60(91%) patients with LA !0.1 ng/mL achieved T 20 ng/dL by week 5. Of all patients (n¼438), 90-96% achieved T 20 ng/dL by week 6 and 90-97% maintained T 20 ng/dL from weeks 6-24.
CONCLUSIONS: These data suggest that SC-LA achieves consistent and prolonged drug delivery and that serum LA levels above 0.1 ng/mL provide favorable T suppression below 20 ng/dL. Consistent achievement of these levels may have implications for improved clinical outcomes, e.g., increased cancer specific and progression free survival. METHODS: We developed three classifiers aimed at predicting 1) high-grade disease on final pathology (primary Gleason grade 4/5) and 2) AP (seminal vesicle or bladder neck invasion or lymph node positive disease). For the development of the Grade Group (GG) classifier, we performed genome-wide differential expression analysis between high-(primary pattern 4/5) and low-(primary pattern 3) Gleason grade disease on 967 high-risk prostate cancer (PCa) patients from the Decipher genomic resource information database (GRIDâ, NCT02609269). For the development of the high-grade disease 1 (HGD) classifier, we used differential expression analysis comparing high (!7) and low ( 4) CAPRA-S scores in a retrospective cohort of 425 high-risk RP patients treated at Mayo Clinic and for HGD 2 classifier, we compared patients with a Decipher score !0.7 and Gleason score !8 to those with lowerrisk scores ina prospective cohort of 1817 high-risk RP patients available in GRID. The GG classifier was trained using a deep neural network model with 3 hidden layers consisting of 79 genes using the 00 h2o 00 package in R v3.1. The HGD 1 and HGD 2 classifiers were based on an elastic net algorithm consisting of109 and60 genes, respectively. Two validation cohorts were used: 1) 6,739 Decipher RP profiles (not used in training) in the GRID ordered by 285 centers over 2015-2016 and 2) a retrospective biopsy (Bx) cohort consisting of 107 Decipher biopsy profiles from 4 academic institutions. Discrimination performance of the classifiers was evaluated via the c-index and logistic regression.
RESULTS: On the RP validation cohort, the GG, HGD 1 and HGD 2 classifiers had c-indices of 0.65 (95% confidence interval [CI] 0.64-0.67), 0.67 (95% CI 0.65-0.69) and 0.69 (95% CI 0.67-0.70) for prediction of the AP endpoint, respectively. On the Bx cohort, the GG, HGD 1 and HGD 2 classifiers had c-indices of 0.80 (95% CI 0.70-0.90), 0.82 (95% CI 0.71-0.93) and 0.84 (95% CI 0.74-0.93), respectively, for the prediction of AP after surgery.
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THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 CONCLUSIONS: GG and HGD classifiers were all predictive of adverse pathology on RP using two validation cohorts of RP and Bx specimens with high accuracy. This study shows how prospective data may be used to develop and validate novel genomic classifiers that provide an independent assessment of high-risk disease at the time of initial diagnosis that complements clinical risk factors and prognostic test to further help optimize treatment decision-making.
Source of Funding: None
MP57-19 TARGETING AKR1C3 ACTIVATION BY INDOMETHACIN OVERCOMES RESISTANCE TO ENZALUTAMIDE AND ABIRATERONE
Chengfei Liu*, Wei Lou, Joy Yang, Chong-Xian Pan, Marc Dall'Era, Christopher Evans, Allen Gao, Sacramento, CA INTRODUCTION AND OBJECTIVES: Resistance of prostate cancer (CaP) cells to enzalutamide and abiraterone, may be mediated by a multitude of survival signaling pathways. In this study we tested whether AKR1C3 activation and intracrine androgens induce CaP cell resistance to enzalutamide and abiraterone and whether targeting these resistance mechanisms overcomes resistance to enzalutamide and abiraterone and thus improve therapy.
METHODS: Global gene expression analysis was analyzed by microarray and transcriptome was analyzed by RNA-seq. Steroid profile including androgens was analyzed by Liquid Chromatography-Mass Spectrometry (LC-MS). The effects of AKR1C3 expression and activation were examined by knock down of AKR1C3 expression by shRNA or inhibition of AKR1C3 enzymatic activity by indomethacin. The effects of AKR1C3 activation on enzalutamide and abiraterone sensitivity were examined in vitro and in vivo. A Phase I/II clinical trial with enzalutamide plus indomethacin has been designed.
RESULTS: Global gene expression analysis showed that steroid biosynthesis pathway is activated in enzalutamide and abiraterone resistant prostate cancer cells. One of the crucial steroidogenic enzymes, AKR1C3, was significantly elevated in enzalutamide/abiraterone resistant cells. In addition, AKR1C3 is highly expressed in metastatic and recurrent prostate cancer and in enzalutamide resistant prostate xenograft tumors. Liquid Chromatography-Mass Spectrometry (LC-MS) analysis of the steroid metabolites revealed that androgen precursors such as cholesterol, DHEA and progesterone, as well as androgens are highly up regulated in enzalutamide/abiraterone resistant prostate cancer cells compared to the parental cells. Knock down of AKR1C3 expression by shRNA or inhibition of AKR1C3 enzymatic activity by indomethacin resensitized enzalutamide/abiraterone resistant prostate cancer cells to enzalutamide/abiraterone treatment both in vitro and in vivo. In contrast, overexpression of AKR1C3 confers resistance to enzalutamide and abiraterone. Furthermore, the combination of indomethacin and enzalutamide/abiraterone resulted in significant inhibition of enzalutamide and abiraterone-resistant tumor growth. These results suggest that AKR1C3 activation is a critical resistance mechanism associated with enzalutamide/abiraterone resistance. In a Phase I/II combination of indomethacin with enzalutamide trial funded by Department of Defense, patients with mCRPC, good performance status (ECOG 0-2) and vital organ function, and no history of enzalutamide or indomethacin treatment will be recruited. The co-primary objective is to assess the toxicity and prostate-specific antigen (PSA) response (¼50% reduction). We will also assess the overall response as determined by the Prostate Cancer Working Group 2 criteria, progression-free survival and molecular correlative studies.
CONCLUSIONS: AKR1C3 activation and resulting in an increase in intracrine androgens are critical resistance mechanisms confer resistance to enzalutamide and abiraterone. Targeting AKR1C3 activation may provide a potential treatment strategy for metastatic prostate cancer patients who develop resistance to enzalutamide and abiraterone.
Source of Funding:
This work is supported in part by grants NIH/NCI This work was supported in part by grants NIH/NCI CA140468, CA168601, CA179970, and DOD PCRP PC150040.
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DIFFERENTIATING CLINICALLY SIGNIFICANT FROM INSIGNIFICANT BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY Alexandr Pinkhasov, Ruben Pinkhasov*, Ahmed Hussein, Kristopher Attwood, Elena Pop, Gaybrielle James, James Mohler, Buffalo, NY INTRODUCTION AND OBJECTIVES: Our group reported on low detectable prostate-specific antigen (PSA) during the first 3 years after radical prostatectomy and proposed criteria to predict subsequent biochemical recurrence (BCR). The purpose of this study is to extend follow-up, add new patients, and compare specific predictors of low detectable PSA that progress to BCR.
METHODS: An institutional database was queried to identify men with ultrasensitive PSA monitoring who underwent open or robotassisted radical prostatectomy (RARP) between Jan 1993 to Dec 2011. Serum PSA and its pattern during the first 3 years of follow-up divided 663 men into 3 groups: 1)undetectable PSA ( detectable PSA in lab where measured), 2) low detectable-stable PSA (!detectable PSA in lab where measured and <0.2 ng/ml, no 2 subsequent increases and/or PSA velocity <0.05 ng/yr), 3)low detectable-unstable PSA (!detectable PSA in lab where measured and <0.2 ng/ml, 2 subsequent increases and/or PSAV !0.05 ng/yr). The primary endpoint was BCR, defined as PSA of 0.2 ng/ml or greater, or receipt of radiation therapy beyond 3 years of follow-up. Time to BCR was summarized using standard Kaplan-Meier and log-rank tests.
RESULTS: The five and ten-year BCR-free survival for all groups was 93% (95% CI: 0.9-0.95) and 73% (95% CI: 0.67-0.79), respectively. Five-year BCR-free survival differed among the 3 groups (p<0.001): 99% (95% CI 0.97-0.99) for undetectable; 89% (95% CI: 0.82-0.94) for low detectable-stable group; and 62% (95% CI: 0.48-0.74) low detectable-unstable group. Ten-year BCR-free survival was 80% (95% CI 0.72-0.86) for undetectable, 67% (95% CI: 0.53-0.78) for low detectable-stable group, and 46% (95% CI: 0.29-0.61) low detectable-unstable group (p<0.001). Low detectable-stable patients were more likely to have lower NCCN risk category (57.3% vs. 39.6%, p¼0.04), low pre-operative PSA (91.2% vs. 88.7%, p¼0.03), and an open procedure (30.1% vs. 15.1%, p¼0.04) than low detectable-unstable patients. No difference in !pT2 stage (31.9% vs. 34%, p¼0.79), pathologic Gleason score >7 (8% vs. 9.4%, p¼0.38), positive margin status (22.1% vs. 24.5%,p¼0.73), or extent of focal margin positivity (44% vs. 61.5%, p¼0.38) was found. CONCLUSIONS: Low detectable PSA patients have risk of BCR more similar to undetectable PSA patients and may warrant monitoring instead of salvage radiation.
